There is hope that the use of ICT/IoT can play a role in preventing the onset and progression of Type 2 Diabetes. In Japan, digitalization has been accelerating due to the Covid-19 pandemic, and in Medicine, online consultations are becoming more commonplace. Currently, various academic conferences are actively discussing the integration of online consultations, self-management using ICT/IoT, and the use of PHR into conventional care. Moreover, there are treatments also known as 'Software as a Medical Device' currently under development, aiming for pharmaceutical approval. Some software, such as those targeting nicotine addiction, hypertension and insomnia, have already been pharmaceutically approved and are now proceeding to obtain insurance coverage. On the other hand, various issues have been identified concerning pharmaceutical application and approval, when considering how these softwares will be used by doctors and will also be covered by health insurance, based on evidence regarding efficacy and safety. Moreover, it is likely in the future that patients will use multiple applications at once, and that there will be exchange of data between these software. This suggests that standardizing data and ensuring compatibility and interoperability between these applications will be crucial.